<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Cutaneous sarcoidosis: Management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Cutaneous sarcoidosis: Management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Cutaneous sarcoidosis: Management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steven Prystowsky, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Miguel Sanchez, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey Callen, MD, FACP, FAAD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Abena O Ofori, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 18, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H323808">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sarcoidosis is a multisystem granulomatous disease characterized by the presence of noncaseating granulomas in organ tissue  (
         <a class="graphic graphic_picture graphicRef80383" href="/z/d/graphic/80383.html" rel="external">
          picture 1
         </a>
         ). Skin involvement is common and may present with a wide variety of clinical manifestations  (
         <a class="graphic graphic_picture graphicRef76184 graphicRef78691 graphicRef52189 graphicRef74163 graphicRef62363" href="/z/d/graphic/76184.html" rel="external">
          picture 2A-E
         </a>
         ).
        </p>
        <p>
         Treatment of cutaneous sarcoidosis is not always necessary. Common reasons for proceeding with treatment include disfiguring, symptomatic, ulcerating, or worsening skin disease. Scientific support for most treatments is limited; accepted therapeutic options include various local and systemic therapies.
        </p>
        <p>
         The treatment of the cutaneous manifestations of sarcoidosis will be reviewed here. The clinical manifestations and diagnosis of cutaneous sarcoidosis and the suggested evaluation for extracutaneous sarcoidosis in patients with cutaneous involvement are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13762.html" rel="external">
          "Cutaneous manifestations of sarcoidosis", section on 'Specific lesions'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13762.html" rel="external">
          "Cutaneous manifestations of sarcoidosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13762.html" rel="external">
          "Cutaneous manifestations of sarcoidosis", section on 'Evaluation for systemic disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The management of extracutaneous sarcoidosis is also reviewed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4359.html" rel="external">
          "Treatment of pulmonary sarcoidosis: Initial approach"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4325.html" rel="external">
          "Treatment of pulmonary sarcoidosis refractory to initial therapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4317.html" rel="external">
          "Gastrointestinal, hepatic, pancreatic, and peritoneal sarcoidosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">
          "Management and prognosis of cardiac sarcoidosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4834.html" rel="external">
          "Neurologic sarcoidosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5583.html" rel="external">
          "Sarcoid arthropathy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7186.html" rel="external">
          "Kidney disease in sarcoidosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/113435.html" rel="external">
          "Sarcoidosis of bone"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5586.html" rel="external">
          "Sarcoid myopathy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H806665488">
         <span class="h1">
          DECISION TO TREAT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although cutaneous sarcoidosis is not life threatening and leads to physical impairment in only a minority of patients, the disease can be disfiguring, and the psychologic and social impact can be devastating. Primary indications for treatment include cosmetically disfiguring, symptomatic, ulcerating, or progressively worsening skin disease. The lupus pernio variant of sarcoidosis has a particularly destructive and disfiguring nature; therefore, treatment of this variant is almost always indicated. For patients with stable, asymptomatic disease that is not cosmetically concerning for the patient, deferring treatment is reasonable. (See
         <a class="medical medical_review" href="/z/d/html/13762.html" rel="external">
          "Cutaneous manifestations of sarcoidosis", section on 'Lupus pernio'
         </a>
         .)
        </p>
        <p>
         The decision to treat is complicated by the unpredictable course of cutaneous sarcoidosis, which includes the possibility for eventual spontaneous remission in up to two-thirds of patients [
         <a href="#rid1">
          1,2
         </a>
         ], as well as a paucity of high-quality studies evaluating treatments. Few randomized trials have evaluated therapies, and evidence on most treatments is primarily limited to small uncontrolled prospective studies, retrospective analyses, and case reports [
         <a href="#rid3">
          3-5
         </a>
         ]. In addition, the response to treatment varies, and some therapies have the potential for serious adverse effects. Thus, when cutaneous involvement is the only indication for treatment, the risks and benefits must be considered carefully.
        </p>
        <p>
         For patients requiring systemic treatment for concomitant extracutaneous sarcoidosis (often systemic glucocorticoid therapy), a separate approach to treatment for skin manifestations is not always necessary. Often, these patients experience simultaneous improvement in cutaneous disease. Patients with insufficient responses may benefit from the addition of a skin-directed approach to treatment. (See
         <a class="local">
          'Initial therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H407048696">
         <span class="h1">
          INITIAL THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Selection of an initial therapy begins with assessment of the extent and severity of disease to determine the most appropriate treatment pathway. The approach can be divided into interventions for localized, extensive, and rapidly progressing or progressively disfiguring disease.
        </p>
        <p class="headingAnchor" id="H3079933124">
         <span class="h2">
          Localized disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The definition of localized disease is not strict but may be considered as limited skin involvement (eg, partial involvement of one or two body areas or a few small lesions in multiple body areas) and skin involvement for which topical or intralesional treatment would not be impractical. Typically, skin involvement is less than 5 percent of the total body surface area.
        </p>
        <p class="headingAnchor" id="H2695795486">
         <span class="h3">
          General approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intralesional or topical corticosteroid therapy is our preferred first-line treatment for localized cutaneous sarcoidosis. Although high-quality evidence to support efficacy is lacking, extensive clinical experience supports a potential for partial or complete clinical improvement.
        </p>
        <p>
         The efficacy of topical and intralesional corticosteroid therapy has not been compared. In our experience, intralesional therapy tends to yield better responses (particularly for lupus pernio and other thick or nodular lesions for which penetration of a topical drug may be insufficient) and is our preferred option for treatment. However, other factors may influence selection between these therapies. For example, intralesional injection can be painful and difficult for some patients to tolerate.
        </p>
        <p>
         Sarcoidosis in sites at greatest risk for corticosteroid-induced skin atrophy (eg, facial, intertriginous, or genital skin) requires a cautious approach to local corticosteroid therapy. (See
         <a class="local">
          'Facial, intertriginous, or genital involvement'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">
          "Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3597806447">
         <span class="h4">
          Intralesional corticosteroid injection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intralesional corticosteroid injection offers the advantage of delivery of high corticosteroid concentrations into the dermis, where granulomas are present:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – We typically initiate treatment with injection of approximately 0.1 mL of a 5 mg/mL concentration of
         <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">
          triamcinolone
         </a>
         acetonide diluted in
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         into each injection site. Injections into lesions larger than 1 cm in diameter are placed approximately 1 cm apart. (See
         <a class="medical medical_review" href="/z/d/html/5568.html" rel="external">
          "Intralesional corticosteroid injection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Treatment is repeated every three to four weeks until lesion resolution, provided noticeable clinical improvement continues. If noticeable improvement does not occur after a treatment with the 5 mg/mL concentration, we increase the concentration to 10 mg/mL at the following treatment session. If progressive improvement is not evident after three or four injection sessions, we typically discontinue this treatment. (See
         <a class="local">
          'Failure of initial therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The pain associated with intralesional injection may be difficult for some patients to tolerate, particularly if the lesions are located in sensitive areas or multiple lesions are present. Potential adverse effects of intralesional corticosteroid therapy include cutaneous atrophy, hypopigmentation, and suppression of the hypothalamic-pituitary-adrenal axis. In order to reduce the risk of the latter, we try not to administer more than 20 mg of
         <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">
          triamcinolone
         </a>
         acetonide per treatment session [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5568.html" rel="external">
          "Intralesional corticosteroid injection", section on 'Adverse effects and pitfalls'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Literature support for intralesional corticosteroid injection for cutaneous sarcoidosis is primarily limited to benefit documented in case series and case reports [
         <a href="#rid7">
          7-9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16714853">
         <span class="h4">
          Topical corticosteroids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Superpotent (group 1) topical corticosteroids, such as
         <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">
          clobetasol
         </a>
         propionate, are typically used for cutaneous sarcoidosis  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid10">
          10-13
         </a>
         ]. Advantages of topical corticosteroid therapy include relative safety, ease of use, and lack of pain associated with administration. A disadvantage of topical therapy may be lower ability to penetrate into the dermis compared with intralesional injections:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – We typically instruct patients to apply the corticosteroid to the affected areas either twice daily or once daily under an occlusive dressing. We re-examine patients approximately every two weeks to assess response and to evaluate for adverse effects. If there is no improvement after four weeks of treatment, we discontinue topical corticosteroids and initiate alternative therapy, typically intralesional corticosteroid injections or systemic therapy. In our experience, topical corticosteroid monotherapy often fails to achieve complete lesion resolution without simultaneously inducing cutaneous atrophy. (See
         <a class="local">
          'Intralesional corticosteroid injection'
         </a>
         above and
         <a class="local">
          'Failure of initial therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition to cutaneous atrophy, hypopigmentation, purpura, and acne can develop with prolonged use of topical corticosteroids, or even with short-term use, when potent corticosteroids are used. Percutaneous absorption of topical corticosteroids is rarely high enough to suppress the hypothalamic-pituitary-adrenal axis, except when high-potency agents are applied over large areas of skin. The local and systemic adverse effects of topical corticosteroids are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">
          "Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Studies evaluating topical corticosteroid therapy are limited. In an uncontrolled study that included patients with a variety of chronic skin diseases, once-weekly application of
         <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">
          clobetasol
         </a>
         propionate lotion under a hydrocolloid dressing led to improvement in sarcoidal papules in all three patients with cutaneous sarcoidosis within three to five weeks [
         <a href="#rid14">
          14
         </a>
         ]. In a separate case report, application of
         <a class="drug drug_general" data-topicid="8514" href="/z/d/drug information/8514.html" rel="external">
          halobetasol
         </a>
         propionate 0.05% ointment twice daily for 10 weeks led to considerable flattening of lesions of lupus pernio [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2844812862">
         <span class="h3">
          Facial, intertriginous, or genital involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to localized cutaneous sarcoidosis on facial, intertriginous, or genital skin differs from disease in other sites because of increased risk for corticosteroid-induced skin atrophy in these areas. In general, we opt for medium-potency (group 4  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 1
         </a>
         )) rather than superpotent topical corticosteroids and often incorporate topical calcineurin inhibitors (
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         or
         <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">
          pimecrolimus
         </a>
         ) as corticosteroid-sparing drugs in the treatment regimen. Of note, early systemic therapy is preferred for patients with unstable disease resulting in worsening facial disfigurement or with extensive skin involvement. (See
         <a class="local">
          'Topical corticosteroids'
         </a>
         above and
         <a class="local">
          'Rapid progression or worsening disfigurement'
         </a>
         below and
         <a class="local">
          'Extensive disease'
         </a>
         below.)
        </p>
        <p>
         In our practices, we typically use topical or intralesional corticosteroids as initial therapy and utilize topical calcineurin inhibitors as a method to reduce corticosteroid use in patients requiring long-term or frequent use to maintain remission.
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          Tacrolimus
         </a>
         0.1% ointment or
         <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">
          pimecrolimus
         </a>
         1% cream is usually applied twice daily, and signs of efficacy are expected within one to three months [
         <a href="#rid16">
          16,17
         </a>
         ]. Topical calcineurin inhibitors are also used in conjunction with local corticosteroids (eg, application of a topical calcineurin inhibitor and topical corticosteroid on alternate weeks). Like topical corticosteroids, limited ability to penetrate into the dermis may inhibit efficacy for thick or nodular lesions.
        </p>
        <p>
         Data on the efficacy of topical calcineurin inhibitors are limited. Successful treatment of cutaneous sarcoidosis with
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         0.03% or 0.1% ointment has been documented in case reports, including one patient who failed to respond to
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         or fumaric acid esters and a second who did not improve with topical or systemic corticosteroids [
         <a href="#rid16">
          16,18-22
         </a>
         ]. Treatment with
         <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">
          pimecrolimus
         </a>
         1% cream has been associated with improvement of papular sarcoidosis and lichenoid cutaneous sarcoidosis in case reports [
         <a href="#rid17">
          17,23
         </a>
         ].
        </p>
        <p>
         Topical
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         and
         <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">
          pimecrolimus
         </a>
         are generally well tolerated and do not induce cutaneous atrophy. A transient burning sensation after application is a common side effect. Tacrolimus 0.03% ointment can be substituted for tacrolimus 0.1% ointment if the former is not tolerated. (See
         <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">
          "Treatment of atopic dermatitis (eczema)", section on 'Topical calcineurin inhibitors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3399235440">
         <span class="h2">
          Extensive disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic agents commonly used for extensive skin involvement (loosely defined as an extent of disease for which topical or intralesional therapy is not practical) or localized involvement that fails to adequately respond to local therapy include antimalarial drugs (
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         or
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         ),
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , and tetracyclines (
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         or
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         ).
        </p>
        <p>
         Oral glucocorticoids are another treatment option. However, due to a broad side effect profile, we generally reserve oral glucocorticoids for rapid disease spread or worsening disfigurement. In contrast to the slower onset of effect of antimalarial drugs,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , and tetracyclines (typically weeks to months), responses to oral glucocorticoids can be rapid. Systemic glucocorticoids are used more routinely in the treatment of pulmonary sarcoidosis [
         <a href="#rid24">
          24
         </a>
         ], but prolonged treatment with these drugs may be associated with lower quality of life [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="local">
          'Rapid progression or worsening disfigurement'
         </a>
         below.)
        </p>
        <p>
         Although antimalarial drugs,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , and tetracyclines are widely used, supporting data are limited and efficacies have not been directly compared. Because of a relatively greater amount of efficacy data on antimalarials and methotrexate, we tend to favor initial treatment with these drugs over tetracyclines, particularly for patients with more severe disease. Treatment selection is also based upon factors such as patient comorbidities, contraindications, adverse effects, and patient comfort with treatment and monitoring regimens.
        </p>
        <p class="headingAnchor" id="H8965351">
         <span class="h3">
          Antimalarials
         </span>
         <span class="headingEndMark">
          —
         </span>
         Benefit of
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         and
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         in cutaneous sarcoidosis is thought to be related to immunomodulatory effects. Antimalarials impede the presentation of antigenic peptides to CD4+ helper T cells and interfere with the release of cytokines and other mediators associated with granuloma formation [
         <a href="#rid26">
          26
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – Typical dosing for adults is 200 to 400 mg per day for
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         and 250 mg per day for
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         . Signs of improvement generally appear after four to six weeks, but treatment should be continued for at least three months to evaluate efficacy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Once satisfactory improvement is achieved, the antimalarial drug can be tapered and discontinued, as tolerated. Tapering regimens are not standardized. In patients who improve on 400 mg of
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         , we often reduce the dose to 200 mg per day following satisfactory improvement. We reassess patients approximately once monthly and continue to taper by reducing the frequency of dosing if the response to treatment is maintained (eg, to 200 mg every other day).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          Hydroxychloroquine
         </a>
         is often preferred over
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         because of a lower risk for antimalarial-induced ocular toxicity, though responses to hydroxychloroquine may be less consistent [
         <a href="#rid4">
          4
         </a>
         ]. To minimize this risk, it is suggested that doses of hydroxychloroquine and chloroquine should not exceed 5 mg/kg and 2.3 mg/kg of real body weight per day, respectively [
         <a href="#rid27">
          27
         </a>
         ]. In addition, patients require baseline and subsequent ophthalmologic examinations. (See
         <a class="medical medical_review" href="/z/d/html/7964.html" rel="external">
          "Antimalarial drugs in the treatment of rheumatic disease", section on 'Adverse effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7964.html" rel="external">
          "Antimalarial drugs in the treatment of rheumatic disease", section on 'Routine eye examinations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other adverse effects of
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         and
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         include gastrointestinal distress, ocular toxicity, and neurologic or hematologic abnormalities. Administration with food may help to minimize nausea. (See
         <a class="medical medical_review" href="/z/d/html/7964.html" rel="external">
          "Antimalarial drugs in the treatment of rheumatic disease", section on 'Adverse effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7964.html" rel="external">
          "Antimalarial drugs in the treatment of rheumatic disease", section on 'Routine eye examinations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Efficacy data are limited to a few small uncontrolled studies, most of which indicate a favorable effect of antimalarials in the majority of treated patients [
         <a href="#rid4">
          4,28
         </a>
         ]. A systematic review of study data prior to 2004 found that 84 of 103 patients (82 percent) treated with
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         or
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         for cutaneous sarcoidosis had a favorable response to therapy [
         <a href="#rid4">
          4
         </a>
         ]. In one uncontrolled study in which 12 of 17 patients improved during hydroxychloroquine therapy, treatment responses were first observed after four weeks; most patients had maximum treatment responses at 12 weeks [
         <a href="#rid29">
          29
         </a>
         ]. Discontinuation of treatment may result in disease relapse [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8965358">
         <span class="h3">
          Methotrexate
         </span>
         <span class="headingEndMark">
          —
         </span>
         The anti-inflammatory properties of
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         are believed to contribute to suppression of granuloma formation in sarcoidosis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <strong>
         </strong>
         Doses of
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         typically range from 10 to 25 mg given
         <strong>
          once weekly
         </strong>
         for adults. A therapeutic response usually is not evident for four to eight weeks and occasionally occurs as long as six months after initiation of treatment [
         <a href="#rid31">
          31,32
         </a>
         ]. In our experience, treating with maximum dosing (25 mg per week) for at least three months is important prior to assuming inefficacy of methotrexate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Upon achievement of satisfactory improvement, the dose of
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         can be tapered. The best regimen for tapering is unknown. We taper methotrexate in 2.5 mg increments weekly, biweekly, or monthly, with the speed of tapering guided by the clinical scenario. Slow tapers may be more appropriate for patients with more severe disease or a history of rapid relapses. Some patients maintain improvement with only 2.5 mg
         <strong>
          per week
         </strong>
         of methotrexate [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Adverse effects include gastrointestinal upset, stomatitis, leukopenia, hepatotoxicity, and pulmonary fibrosis.
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          Folic acid
         </a>
         (1 mg daily) or folinic acid (2.5 mg weekly) supplementation reduces the likelihood of some adverse effects [
         <a href="#rid34">
          34
         </a>
         ]. In addition to numerous drug interactions that increase the risk of
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         toxicity, pre-existing liver disease and alcohol abuse are contraindications to methotrexate due to the risk for hepatotoxicity. Dosing of methotrexate must be adjusted in patients with renal disease. (See
         <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">
          "Major side effects of low-dose methotrexate"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7507.html" rel="external">
          "Use of methotrexate in the treatment of rheumatoid arthritis", section on 'Folic acid supplementation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          Methotrexate
         </a>
         is teratogenic and should not be given to pregnant women. Precautions for both men and women are also indicated prior to attempts to conceive. (See
         <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">
          "Major side effects of low-dose methotrexate", section on 'Pregnancy risk'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – The efficacy of
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         for cutaneous sarcoidosis has been documented in small uncontrolled studies and case reports [
         <a href="#rid31">
          31,35-38
         </a>
         ]. In an uncontrolled study of 16 patients with cutaneous sarcoidosis who were treated with methotrexate (25 mg per
         <strong>
          week
         </strong>
         ) followed by a taper to 5 to 15 mg per week upon improvement, lesions completely resolved in 12 patients (75 percent), and the remaining 4 patients had partial improvement [
         <a href="#rid33">
          33
         </a>
         ]. In a case series that included 50 patients with sarcoidosis treated with methotrexate at doses between 10 and 15 mg per
         <strong>
          week
         </strong>
         for at least two years, skin lesions improved in 16 of 17 patients with cutaneous sarcoidosis [
         <a href="#rid35">
          35
         </a>
         ]. Relapse was common after the discontinuation of therapy. In a retrospective analysis of 26 patients treated only with 7.5 mg methotrexate
         <strong>
          weekly
         </strong>
         ,
         <strong>
         </strong>
         37 percent
         <strong>
         </strong>
         of 11 patients with cutaneous sarcoidosis reported improvement in skin lesions [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8966978">
         <span class="h3">
          Tetracyclines
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mechanism of action of tetracyclines (eg,
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         ) in sarcoidosis is not fully understood but is thought to involve immunomodulatory inhibition of granuloma formation rather than an antimicrobial effect [
         <a href="#rid40">
          40-42
         </a>
         ].
        </p>
        <p>
         Although tetracyclines are given for cutaneous sarcoidosis, data to support efficacy are weak. The relatively favorable side effect profiles of these drugs contribute to their status as alternative systemic medications for cutaneous sarcoidosis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – The typical dose of
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         and
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         used in adults is 100 mg twice daily. In our experience, responses are typically seen within one to three months. Upon achievement of a satisfactory response, the dose can be tapered. The best method of tapering is unclear. Tapering to 100 mg per day and lower daily doses based upon maintenance of response is reasonable.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Potential adverse effects of tetracyclines include photosensitivity, pigment changes in teeth and skin  (
         <a class="graphic graphic_picture graphicRef79772" href="/z/d/graphic/79772.html" rel="external">
          picture 3
         </a>
         ), and gastrointestinal distress.
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          Minocycline
         </a>
         is less likely to cause photosensitivity but has been associated with dizziness and a lupus-like syndrome. (See
         <a class="medical medical_review" href="/z/d/html/494.html" rel="external">
          "Tetracyclines", section on 'Adverse reactions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – The efficacy of
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         is supported by an uncontrolled study in which 12 patients with cutaneous sarcoidosis (9 of whom had previously failed treatment with antimalarials) were treated with minocycline 100 mg twice daily for a median of 12 months [
         <a href="#rid43">
          43
         </a>
         ]. Skin lesions completely resolved in eight patients (67 percent) and partially improved in two patients (17 percent). Most of the responders (seven patients) showed initial signs of improvement within one month, and the time to achieve maximal improvement ranged from one to six months. Patients remained in remission for an average of 15.3 months (range 1 to 33 months) after the discontinuation of therapy. The three patients who relapsed after the cessation of minocycline subsequently responded to
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         100 mg twice daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A benefit of
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         for cutaneous sarcoidosis is also suggested by a retrospective study that found that 20 of 27 patients with non-lupus pernio cutaneous sarcoidosis achieved complete remission (6 patients) or partial improvement (14 patients) after treatment with minocycline [
         <a href="#rid44">
          44
         </a>
         ]. In addition, improvement in subcutaneous and tattoo sarcoidosis with
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         has been reported [
         <a href="#rid45">
          45,46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1518742983">
         <span class="h2">
          Rapid progression or worsening disfigurement
         </span>
         <span class="headingEndMark">
          —
         </span>
         A more aggressive approach is indicated for patients experiencing rapid spread of skin involvement or worsening disfigurement due to cutaneous sarcoidosis  (
         <a class="graphic graphic_algorithm graphicRef120775" href="/z/d/graphic/120775.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2293931068">
         <span class="h3">
          Systemic glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic glucocorticoid therapy is not used for most patients with isolated cutaneous sarcoidosis because of the potential for serious side effects with long-term glucocorticoid therapy. However, because systemic glucocorticoid therapy may induce rapid improvement, it is the initial treatment of choice for rapidly progressive or progressively disfiguring sarcoidosis. It is important to lower the dose of glucocorticosteroids as rapidly as possible to minimize exposure, so treatment is often combined with a glucocorticoid-sparing agent:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – The optimal regimen for systemic glucocorticoid therapy is unknown, and various regimens have been described [
         <a href="#rid12">
          12,47
         </a>
         ]. In our practice, we begin with 0.5 mg/kg per day of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         . Clinically significant improvement usually occurs within two weeks, and marked improvement is expected within three to four weeks. Tapering of prednisone by 5 mg per week can be attempted in patients who respond well to the initial 0.5 mg/kg per day dose. If disease activity recurs, we return to the lowest effective dose of prednisone and add a glucocorticoid-sparing agent (usually
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         or
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ) prior to additional attempts at tapering.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If clinically significant improvement is not evident after two weeks of 0.5 mg/kg per day of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , we increase the dose to 1 mg/kg per day and initiate simultaneous treatment with a glucocorticoid-sparing agent (usually
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         or
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ). Improvement is expected within three to four weeks. Once satisfactory improvement is attained, we taper the dose of prednisone by 10 mg per week.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Calcium and vitamin D supplementation for prevention of osteoporosis are generally recommended for patients who receive long-term glucocorticoids; however, because patients with sarcoidosis may have associated hypercalcemia, caution is indicated in this population. (See
         <a class="medical medical_review" href="/z/d/html/841.html" rel="external">
          "Hypercalcemia in granulomatous diseases"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2023.html" rel="external">
          "Calcium and vitamin D supplementation in osteoporosis", section on 'Granulomatous diseases'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The adverse effects of systemic glucocorticoid therapy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Although systemic glucocorticoids are considered the standard of care for rapidly progressive or progressively disfiguring sarcoidosis, no randomized trials have evaluated efficacy for cutaneous sarcoidosis [
         <a href="#rid48">
          48-53
         </a>
         ]. In a retrospective study of 116 treatment courses in 54 patients with lupus pernio, monotherapy with systemic glucocorticoids was associated with complete or near resolution of lupus pernio lesions in 20 percent of treatment courses and at least some improvement in 72 percent [
         <a href="#rid50">
          50
         </a>
         ]. In addition, a 1997 systematic review of published reports found that skin lesions resolved in 12 of 16 patients with ulcerative sarcoidosis who were treated with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         as monotherapy [
         <a href="#rid48">
          48
         </a>
         ], and a small retrospective study and case series have documented improvement in subcutaneous sarcoidosis during treatment with systemic glucocorticoids [
         <a href="#rid49">
          49,51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4359.html" rel="external">
          "Treatment of pulmonary sarcoidosis: Initial approach", section on 'Efficacy of glucocorticoids'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3907385096">
         <span class="h1">
          FAILURE OF INITIAL THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who fail to respond to one of the suggested initial therapies may benefit from trials of other first-line therapies prior to proceeding to treatments for refractory disease. For example, patients with inadequate responses of localized disease to topical or intralesional corticosteroid therapy are candidates for systemic treatment with antimalarial drugs,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , or tetracyclines, and patients who respond poorly to one of these systemic drugs may achieve a better response to one of the other systemic agents [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="local">
          'Extensive disease'
         </a>
         above.)
        </p>
        <p>
         In addition, topical or intralesional corticosteroid therapy may be used as an adjunctive intervention in patients who achieve only partial responses to systemic therapy [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8965978">
         <span class="h1">
          REFRACTORY DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients, especially those with eruptive skin lesions, rapidly progressive cutaneous disease, or lupus pernio, may fail to respond to systemic glucocorticoids, antimalarials,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , and tetracyclines. Tumor necrosis factor (TNF)-alpha inhibitors (
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         or
         <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">
          adalimumab
         </a>
         ) and
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         are our preferred next-line therapies for these patients. However, efficacy data are limited, and further study is necessary to confirm the effects of these interventions. Infliximab is the most studied agent [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         TNF-alpha plays an important role in the pathogenesis of sarcoidosis [
         <a href="#rid54">
          54
         </a>
         ]. Agents that suppress TNF are thought to contribute to the inhibition of granuloma formation in sarcoidosis [
         <a href="#rid54">
          54
         </a>
         ]. Paradoxically, multiple occurrences of TNF-alpha inhibitor-induced sarcoidosis have been reported, contributing to reservation of these drugs for refractory cases [
         <a href="#rid55">
          55-64
         </a>
         ].
        </p>
        <p>
         Efficacy of different TNF-alpha inhibitors for cutaneous sarcoidosis does not appear to be equivalent. Limited data suggest
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         may be less effective than
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         and
         <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">
          adalimumab
         </a>
         [
         <a href="#rid65">
          65,66
         </a>
         ]. Additional study is necessary to clarify the effects of other TNF-alpha inhibitors, including
         <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">
          golimumab
         </a>
         and certolizumab [
         <a href="#rid5">
          5,67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1706660">
         <span class="h2">
          Infliximab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          Infliximab
         </a>
         is an intravenously administered, chimeric, monoclonal antibody directed against TNF-alpha. Optimal dosing for cutaneous sarcoidosis has not been established. Often, 3 to 5 mg/kg is given at weeks 0, 2, and 6, and then every six weeks [
         <a href="#rid50">
          50,68
         </a>
         ]. A panel of sarcoidosis experts suggested maintenance dosing every four weeks rather than every six weeks; however these recommendations were not specific for cutaneous sarcoidosis, and consideration of other maintenance doses was suggested based upon disease activity [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
         Data on
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         therapy are limited [
         <a href="#rid70">
          70
         </a>
         ]. A randomized trial of 138 patients with pulmonary sarcoidosis compared the efficacy of 5 mg/kg of infliximab, 3 mg/kg of infliximab, or placebo given at 0, 2, 6, 12, 18, and 24 weeks [
         <a href="#rid68">
          68
         </a>
         ]. Analyses of the trial data revealed no significant differences in the response of lupus pernio (n = 19) or all forms of cutaneous sarcoidosis (n = 36) among the three groups [
         <a href="#rid68">
          68,71
         </a>
         ]. However, in a subset analysis in which the response of patients with chronic facial sarcoidosis was assessed with an alternative scoring tool, infliximab therapy was superior to placebo for improving desquamation and induration but not erythema, area of involvement, or photographic assessment at 24 weeks [
         <a href="#rid72">
          72
         </a>
         ]. Also, a systematic review of nonrandomized studies found an overall complete or partial response rate of 89 percent among 84 patients [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
         The onset of action of
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         may be delayed. In one of the largest observational studies that included 46 patients with sarcoidosis and skin involvement (primarily lupus pernio, nodules, or plaques), the overall cutaneous response rate (including complete and partial responses) to anti-TNF therapy was 24 percent after 3 months, 46 percent after 6 months, and 79 percent after 12 months [
         <a href="#rid55">
          55
         </a>
         ]. Patients received infliximab with or without concomitant systemic glucocorticoids or immunosuppressants.
        </p>
        <p>
         Improvement in extracutaneous sarcoidosis has been reported during treatment with biosimilars for
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         ; however, efficacy of biosimilars for infliximab for cutaneous sarcoidosis is unclear [
         <a href="#rid73">
          73-75
         </a>
         ].
        </p>
        <p>
         Adverse effects of
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         include infusion reactions and an increased risk for infections. The side effects of biologic TNF inhibitors are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7970.html" rel="external">
          "Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1410.html" rel="external">
          "Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7975.html" rel="external">
          "Tumor necrosis factor-alpha inhibitors: Risk of malignancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1707240">
         <span class="h2">
          Adalimumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">
          Adalimumab
         </a>
         is an anti-TNF human monoclonal antibody that may be effective for cutaneous sarcoidosis. Optimal dosing specifically for cutaneous disease has not been established. Our typical regimen consists of an initial 80 mg dose at week 0 followed by 40 mg given at week 1 and then once weekly.
        </p>
        <p>
         Favorable results have been observed in a small randomized trial, case reports, and a case series [
         <a href="#rid65">
          65,76-81
         </a>
         ]. Benefit has also been reported in extracutaneous sarcoidosis. (See
         <a class="medical medical_review" href="/z/d/html/4325.html" rel="external">
          "Treatment of pulmonary sarcoidosis refractory to initial therapy", section on 'Tumor necrosis factor-alpha antagonists'
         </a>
         .)
        </p>
        <p>
         In the randomized trial, 10 patients with cutaneous sarcoidosis were treated with either
         <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">
          adalimumab
         </a>
         (80 mg at week 0 followed by 40 mg once weekly) or a placebo agent for 12 weeks [
         <a href="#rid80">
          80
         </a>
         ]. Continuation of other systemic medications was allowed provided the dose remained relatively stable. The trial found that 5 of 10 patients in the adalimumab group versus 1 of 5 patients in the placebo group achieved at least a two-grade improvement in the physician global assessment score, a difference that was not statistically significant. However, at the end of the additional 12-week, open-label phase, statistically significant improvement was found in the target lesion area among patients given adalimumab. This study has been criticized because of its small size, lack of statistical significance in its primary and secondary outcomes studied, miscalculation of statistical analysis of the primary outcome, and failure to include an intent-to-treat analysis [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
         Case reports have described use of other
         <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">
          adalimumab
         </a>
         regimens for cutaneous sarcoidosis, including the exclusion of an 80 mg loading dose, the administration of 40 mg every other week rather than once weekly, and the administration of 80 mg once weekly [
         <a href="#rid65">
          65,76-81
         </a>
         ]. Larger, randomized trials are necessary to confirm the efficacy of adalimumab for cutaneous sarcoidosis [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2163944">
         <span class="h2">
          Thalidomide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          Thalidomide
         </a>
         inhibits TNF-alpha and interferon (IFN)-gamma, the major cytokines that drive granuloma formation in sarcoidosis, as well as other factors [
         <a href="#rid84">
          84-86
         </a>
         ]. Uncontrolled studies and case reports suggest that thalidomide may be effective for cutaneous sarcoidosis [
         <a href="#rid86">
          86-91
         </a>
         ]. Although beneficial effects of 100 mg per day of thalidomide were not confirmed in a small, randomized trial that evaluated thalidomide in a dose of 100 mg per day [
         <a href="#rid92">
          92
         </a>
         ], benefit has been reported in uncontrolled studies using thalidomide doses higher than 100 mg per day.
        </p>
        <p>
         When treating refractory cutaneous sarcoidosis with
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         , we initiate therapy with a dose of 100 mg per day and gradually escalate the dose to 200 mg. However, sedation and neuropathy increase with higher doses. Because of safety concerns, we generally limit thalidomide therapy to three months. Further study is necessary to clarify the efficacy of thalidomide and its derivatives. (See
         <a class="medical medical_review" href="/z/d/html/13775.html" rel="external">
          "Management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus refractory to antimalarial therapy", section on 'Thalidomide'
         </a>
         .)
        </p>
        <p>
         In the three-month, randomized, investigator-masked, multicenter trial, patients with chronic (≥12 months) and disfiguring or extensive cutaneous sarcoidosis were randomly assigned to receive
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         100 mg once daily (20 patients) or oral placebo (19 patients) [
         <a href="#rid92">
          92
         </a>
         ]. Three target skin lesions were assessed for area and infiltration monthly; patients were classified as responders if they exhibited at least 50 percent reductions in both the area and infiltration of all three target skin lesions as well as no new lesions and a lack of marked deterioration of nontarget lesions. After three months, there was no difference in the response rate between the two groups. In the thalidomide group, 4 of 20 patients (20 percent) were responders versus 4 of 19 patients (21 percent) in the placebo group. No patients achieved a complete response, and four patients in the thalidomide group discontinued treatment early because of adverse effects. Patients who discontinued treatment were analyzed as treatment failures. Limitations of this trial include the short duration, relatively low dose of thalidomide, and limited power.
        </p>
        <p>
         Larger trials are necessary to confirm these findings and to determine whether better results may be obtained with different
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         regimens. Analysis of an open-label, follow-up phase that followed the randomized trial suggests a beneficial effect of thalidomide doses above 100 mg daily [
         <a href="#rid92">
          92
         </a>
         ]. After an additional three months of open-label thalidomide therapy (up to 200 mg per day), 6 of the 14 patients who had been in the thalidomide arm of the study and were available for clinical evaluation achieved complete healing and four achieved lesser improvement, according to the investigator assessment. Among the 14 patients from the original placebo arm of the study available for evaluation after three months of thalidomide, two had complete responses and eight had lesser degrees of improvement.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          Thalidomide
         </a>
         is teratogenic. In the United States, patient and provider participation in the THALOMID Risk Evaluation and Mitigation Strategy (REMS) program (www.thalomidrems.com) is mandatory in order for this drug to be prescribed and dispensed. Other adverse effects associated with thalidomide include somnolence, peripheral neuropathy, thrombosis, constipation, endocrine dysfunction, and neutropenia. (See
         <a class="drug drug_general" href="/z/d/drug information/10095.html" rel="external">
          "Thalidomide: Drug information"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          Lenalidomide
         </a>
         (a
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         analog with a safer adverse effect profile) was reported to markedly improve lupus pernio in a patient who had not responded to systemic corticosteroids and
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         and had not been able to tolerate
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         or thalidomide [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
         Biosimilar anti-TNF-alpha agents appear to be promising but have not been studied in sarcoidosis [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3871469452">
         <span class="h1">
          OTHER THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple other interventions, including systemic and intralesional agents, phototherapy, laser therapy, and surgical excision, have been used for patients with refractory cutaneous sarcoidosis; however, the limited data to support efficacy of these agents precludes recommendations for their routine use.
        </p>
        <p class="headingAnchor" id="H2663582792">
         <span class="h2">
          Janus kinase inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited data suggest that Janus kinase (JAK) inhibitors may be effective treatments for cutaneous and systemic organ sarcoidosis. These agents eradicate signal transducer and activator of transcription (STAT) 1 and 3, as well as normalize cytokines that are associated with the formation of granulomas in sarcoidosis.
        </p>
        <p>
         Complete and partial responses of cutaneous sarcoidosis to oral JAK inhibitors have been documented in case reports, including several patients with prolonged disease that had responded poorly to other therapeutic agents [
         <a href="#rid94">
          94-97
         </a>
         ]. Most patients have been treated with the JAK1, JAK2, and JAK3 inhibitor
         <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">
          tofacitinib
         </a>
         , but some patients have been treated with
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         , a JAK1 and JAK2 inhibitor.
        </p>
        <p>
         A steroid-sparing effect was observed in a small, 16-week, open-label, prospective study [
         <a href="#rid98">
          98
         </a>
         ]. After four weeks on
         <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">
          tofacitinib
         </a>
         , the dose of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         could be gradually reduced by at least 50 percent to less than 5 mg in three of five patients (one was lost to follow-up, and the other withdrew due to deteriorating, neurologic complications).
        </p>
        <p>
         Compounded
         <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">
          tofacitinib
         </a>
         2% ointment applied to lesions twice daily has appeared partially effective in case reports. In one patient, treatment of scalp sarcoidosis was associated with a partial response, with improvement in erythema, scaling, and induration [
         <a href="#rid99">
          99
         </a>
         ]. In another report, improvement of erythema and induration was noted in angiolupoid sarcoidosis of the nose beginning at 10 weeks, with minimal activity present at 18 months [
         <a href="#rid100">
          100
         </a>
         ]. Telangiectasias were treated with a pulsed dye laser (PDL).
        </p>
        <p class="headingAnchor" id="H3454886761">
         <span class="h2">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         Examples of additional systemic agents for which uncontrolled studies, case series, or case reports have suggested benefit in patients with sarcoidosis include
         <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">
          allopurinol
         </a>
         [
         <a href="#rid101">
          101-108
         </a>
         ],
         <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">
          apremilast
         </a>
         [
         <a href="#rid109">
          109
         </a>
         ],
         <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">
          chlorambucil
         </a>
         [
         <a href="#rid110">
          110
         </a>
         ],
         <a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">
          dimethyl fumarate
         </a>
         [
         <a href="#rid111">
          111
         </a>
         ],
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          isotretinoin
         </a>
         [
         <a href="#rid112">
          112-114
         </a>
         ],
         <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">
          leflunomide
         </a>
         [
         <a href="#rid115">
          115-117
         </a>
         ], melatonin [
         <a href="#rid118">
          118,119
         </a>
         ],
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil [
         <a href="#rid120">
          120
         </a>
         ], and tranilast [
         <a href="#rid121">
          121
         </a>
         ]. Intralesional therapies have included intralesional
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         [
         <a href="#rid122">
          122
         </a>
         ] and intralesional
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         [
         <a href="#rid123">
          123
         </a>
         ]. A single-blind randomized trial suggested benefit of an oral antimycobacterial regimen with concomitant
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         [
         <a href="#rid124">
          124
         </a>
         ].
        </p>
        <p>
         There are case reports that describe improvement in cutaneous sarcoidosis associated with ultraviolet A1 (UVA1; 340 to 400 nm) phototherapy [
         <a href="#rid125">
          125,126
         </a>
         ]. In addition, successful treatment with topical psoralen plus ultraviolet A (PUVA) therapy has been documented in a case report and small case series [
         <a href="#rid127">
          127,128
         </a>
         ].
        </p>
        <p>
         Various lasers have been used for cutaneous sarcoidosis [
         <a href="#rid129">
          129
         </a>
         ]. Improvements in lesions of lupus pernio, nodular sarcoidosis, and scar sarcoidosis have been reported in patients treated with PDLs [
         <a href="#rid130">
          130-134
         </a>
         ]. Moreover, responses to treatment with a 532 nm frequency-doubled neodymium-doped:yttrium aluminium garnet (Nd:YAG) laser [
         <a href="#rid135">
          135,136
         </a>
         ], Q-switched ruby laser [
         <a href="#rid137">
          137
         </a>
         ], ablative carbon dioxide laser [
         <a href="#rid138">
          138-140
         </a>
         ], and erbium:yttrium aluminum garnet (Er:YAG) laser have been documented [
         <a href="#rid136">
          136
         </a>
         ].
        </p>
        <p>
         Improvements have been noted in several patients after treatment with photodynamic therapy [
         <a href="#rid141">
          141-145
         </a>
         ]. In our experience, relapses are common after this treatment.
        </p>
        <p>
         Surgical excision of cutaneous sarcoidosis lesions is rarely performed due to the potential for sarcoidosis to recur in surgical scars. However, improvement in cosmetic appearance has been reported in patients with severely disfiguring lesions on the nose after reconstructive surgery [
         <a href="#rid146">
          146,147
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13762.html" rel="external">
          "Cutaneous manifestations of sarcoidosis", section on 'Scar sarcoidosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H261655666">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116637.html" rel="external">
          "Society guideline links: Sarcoidosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H324690">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Sarcoidosis is a multisystem granulomatous disorder that can present with skin involvement  (
         <a class="graphic graphic_picture graphicRef76184 graphicRef78691 graphicRef52189 graphicRef74163 graphicRef62363" href="/z/d/graphic/76184.html" rel="external">
          picture 2A-E
         </a>
         ). Although a variety of therapies have been used for cutaneous sarcoidosis, high-quality evidence to support the efficacy of these treatments is limited. Treatment can be challenging and is individualized because of the variability of clinical presentations, diversity of systemic organ involvement, variability of the risk for adverse effects among patients, and financial factors. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Initial therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Decision to treat
         </strong>
         – Treatment is not required for all patients with cutaneous sarcoidosis. Spontaneous resolution is possible. In the absence of extracutaneous indications for the treatment of sarcoidosis, treatment should be considered for patients with cosmetically disfiguring, symptomatic, ulcerating, or progressively worsening skin disease. Patients with stable disease that is not bothersome do not require therapy. Treatment is usually required for lupus pernio due to the disfiguring nature of this variant. (See
         <a class="local">
          'Decision to treat'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of localized disease
         </strong>
         – Patients with a limited number of skin lesions may benefit from local therapies. For patients with localized disease on the trunk or extremities, we suggest initiating treatment with superpotent topical corticosteroids or intralesional corticosteroid injections (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Increased risk for corticosteroid-induced skin atrophy warrants a more cautious approach to local corticosteroid therapy in patients with facial or intertriginous skin involvement. (See
         <a class="local">
          'Localized disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of extensive or resistant disease
         </strong>
         – Some patients do not respond sufficiently to local therapy or have widespread disease that makes local therapy impractical. For these patients, we suggest initial treatment with antimalarial agents or
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          Minocycline
         </a>
         and
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         are alternative systemic therapies. (See
         <a class="local">
          'Extensive disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of rapidly progressing or disfiguring disease
         </strong>
         – For patients experiencing rapid disease progression or worsening disfigurement, we suggest a systemic glucocorticoid as initial therapy  (
         <a class="graphic graphic_algorithm graphicRef120775" href="/z/d/graphic/120775.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Rapid progression or worsening disfigurement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Refractory disease
         </strong>
         – For patients who fail to improve with the suggested initial therapies for cutaneous sarcoidosis, we suggest a trial of anti-tumor necrosis factor (TNF) therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Therapeutic options include
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">
          adalimumab
         </a>
         , and
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         . (See
         <a class="local">
          'Refractory disease'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baughman RP, Lower EE. Evidence-based therapy for cutaneous sarcoidosis. Clin Dermatol 2007; 25:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mosam A, Morar N. Recalcitrant cutaneous sarcoidosis: an evidence-based sequential approach. J Dermatolog Treat 2004; 15:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dai C, Shih S, Ansari A, et al. Biologic Therapy in the Treatment of Cutaneous Sarcoidosis: A Literature Review. Am J Clin Dermatol 2019; 20:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jarratt MT, Spark RF, Arndt KA. The effects of intradermal steroids on the pituitary-adrenal axis and the skin. J Invest Dermatol 1974; 62:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russo G, Millikan LE. Cutaneous sarcoidosis: diagnosis and treatment. Compr Ther 1994; 20:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SULLIVAN RD, MAYOCK RL, JONES R Jr. Local injection of hydrocortisone and cortisone into skin lesions of sarcoidosis. J Am Med Assoc 1953; 152:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verbov J. The place of intralesional steroid therapy in dermatology. Br J Dermatol 1976; 94 suppl 12:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wise RD. Clinical resolution of facial cutaneous sarcoidosis with systemic colchicine and a topical corticosteroid ointment. Compr Ther 2008; 34:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chong WS, Tan HH, Tan SH. Cutaneous sarcoidosis in Asians: a report of 25 patients from Singapore. Clin Exp Dermatol 2005; 30:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Badgwell C, Rosen T. Cutaneous sarcoidosis therapy updated. J Am Acad Dermatol 2007; 56:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doherty CB, Rosen T. Evidence-based therapy for cutaneous sarcoidosis. Drugs 2008; 68:1361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Volden G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Derm Venereol 1992; 72:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khatri KA, Chotzen VA, Burrall BA. Lupus pernio: successful treatment with a potent topical corticosteroid. Arch Dermatol 1995; 131:617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green CM. Topical tacrolimus for the treatment of cutaneous sarcoidosis. Clin Exp Dermatol 2007; 32:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           La Placa M, Balestri R, Mega C, et al. Disfiguring papular sarcoidosis of the face: dramatic improvement with pimecrolimus. J Eur Acad Dermatol Venereol 2015; 29:2497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Francesco V, Cathryn AS, Piccirillo F. Successful topical treatment of cutaneous sarcoidosis with macrolide immunomodulators. Eur J Dermatol 2007; 17:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gutzmer R, Völker B, Kapp A, Werfel T. [Successful topical treatment of cutaneous sarcoidosis with tacrolimus]. Hautarzt 2003; 54:1193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katoh N, Mihara H, Yasuno H. Cutaneous sarcoidosis successfully treated with topical tacrolimus. Br J Dermatol 2002; 147:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vano-Galvan S, Fernandez-Guarino M, Carmona LP, et al. Lichenoid type of cutaneous sarcoidosis: great response to topical tacrolimus. Eur J Dermatol 2008; 18:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landers MC, Skokan M, Law S, Storrs FJ. Cutaneous and pulmonary sarcoidosis in association with tattoos. Cutis 2005; 75:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tammaro A, Abruzzese C, Narcisi A, et al. Topical pimecrolimus as a new optional treatment in cutaneous sarcoidosis of lichenoid type. Case Rep Dermatol Med 2014; 2014:976851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drent M, Crouser ED, Grunewald J. Challenges of Sarcoidosis and Its Management. N Engl J Med 2021; 385:1018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Judson MA, Chaudhry H, Louis A, et al. The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis. Respir Med 2015; 109:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 2007; 20:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marmor MF, Kellner U, Lai TY, et al. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology 2016; 123:1386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zic JA, Horowitz DH, Arzubiaga C, King LE Jr. Treatment of cutaneous sarcoidosis with chloroquine. Review of the literature. Arch Dermatol 1991; 127:1034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol 1990; 23:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siltzbach LE, Teirstein AS. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand Suppl 1964; 425:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Webster GF, Razsi LK, Sanchez M, Shupack JL. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol 1991; 24:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baughman RP, Lynch JP. Difficult treatment issues in sarcoidosis. J Intern Med 2003; 253:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veien NK, Brodthagen H. Cutaneous sarcoidosis treated with methotrexate. Br J Dermatol 1977; 97:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shea B, Swinden MV, Tanjong Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2013; :CD000951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995; 155:846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaye O, Palazzo E, Grossin M, et al. Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis. Br J Rheumatol 1995; 34:642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gedalia A, Molina JF, Ellis GS Jr, et al. Low-dose methotrexate therapy for childhood sarcoidosis. J Pediatr 1997; 130:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacher MJ. Spontaneous remission or response to methotrexate in sarcoidosis. Ann Intern Med 1968; 69:1247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isshiki T, Yamaguchi T, Yamada Y, et al. Usefulness of low-dose methotrexate monotherapy for treating sarcoidosis. Intern Med 2013; 52:2727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lodha S, Sanchez M, Prystowsky S. Sarcoidosis of the skin: a review for the pulmonologist. Chest 2009; 136:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Webster GF, Toso SM, Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C. Arch Dermatol 1994; 130:748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szeto GL, Brice AK, Yang HC, et al. Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells. J Infect Dis 2010; 201:1132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bachelez H, Senet P, Cadranel J, et al. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 2001; 137:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steen T, English JC. Oral minocycline in treatment of cutaneous sarcoidosis. JAMA Dermatol 2013; 149:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El Sayed F, Dhaybi R, Ammoury A. Subcutaneous nodular sarcoidosis and systemic involvement successfully treated with doxycycline. J Med Liban 2006; 54:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antonovich DD, Callen JP. Development of sarcoidosis in cosmetic tattoos. Arch Dermatol 2005; 141:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose AS, Tielker MA, Knox KS. Hepatic, ocular, and cutaneous sarcoidosis. Clin Chest Med 2008; 29:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albertini JG, Tyler W, Miller OF 3rd. Ulcerative sarcoidosis. Case report and review of the literature. Arch Dermatol 1997; 133:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcoval J, Maña J, Moreno A, Peyri J. Subcutaneous sarcoidosis--clinicopathological study of 10 cases. Br J Dermatol 2005; 153:790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stagaki E, Mountford WK, Lackland DT, Judson MA. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest 2009; 135:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed I, Harshad SR. Subcutaneous sarcoidosis: is it a specific subset of cutaneous sarcoidosis frequently associated with systemic disease? J Am Acad Dermatol 2006; 54:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           James DG, Carstairs LS, Trowell J, Sharma OP. Treatment of sarcoidosis. Report of a controlled therapeutic trial. Lancet 1967; 2:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johns CJ, Michele TM. The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. Medicine (Baltimore) 1999; 78:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antoniu SA. Targeting the TNF-alpha pathway in sarcoidosis. Expert Opin Ther Targets 2010; 14:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heidelberger V, Ingen-Housz-Oro S, Marquet A, et al. Efficacy and Tolerance of Anti-Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis: A French Study of 46 Cases. JAMA Dermatol 2017; 153:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhaille F, Viseux V, Caudron A, et al. Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases. Dermatology 2010; 220:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daïen CI, Monnier A, Claudepierre P, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 2009; 48:883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sturfelt G, Christensson B, Bynke G, Saxne T. Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab. J Rheumatol 2007; 34:2313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almodóvar R, Izquierdo M, Zarco P, et al. Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2007; 25:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fok KC, Ng WW, Henderson CJ, Connor SJ. Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab. J Crohns Colitis 2012; 6:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burns AM, Green PJ, Pasternak S. Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab. J Cutan Pathol 2012; 39:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clementine RR, Lyman J, Zakem J, et al. Tumor necrosis factor-alpha antagonist-induced sarcoidosis. J Clin Rheumatol 2010; 16:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toussirot E, Pertuiset E, Kantelip B, Wendling D. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol 2008; 26:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amber KT, Bloom R, Mrowietz U, Hertl M. TNF-α: a treatment target or cause of sarcoidosis? J Eur Acad Dermatol Venereol 2015; 29:2104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Field S, Regan AO, Sheahan K, Collins P. Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept. Clin Exp Dermatol 2010; 35:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thielen AM, Barde C, Saurat JH, Laffitte E. Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists. Dermatology 2009; 219:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Judson MA, Baughman RP, Costabel U, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J 2014; 44:1296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drent M, Cremers JP, Jansen TL, Baughman RP. Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adler BL, Wang CJ, Bui TL, et al. Anti-tumor necrosis factor agents in sarcoidosis: A systematic review of efficacy and safety. Semin Arthritis Rheum 2019; 48:1093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008; 31:1189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baughman RP, Judson MA, Lower EE, et al. Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Dis 2016; 32:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veltkamp M, Drent M, Baughman RP. Infliximab or biosimilars in sarcoidosis; to switch or not to switch? Sarcoidosis Vasc Diffuse Lung Dis 2016; 32:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vorselaars AD, Van Beek FT, Crommelin HC, et al. Promising results of the infliximab Biosimilar Inflectra in severe sarcoidosis patients. B104 Sarcoidosis: Clinical studies on diagnosis, prognosis and therapy. Am J Respir Crit Care Med 2017; 195:A4756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schimmelpennink MC, Vorselaars ADM, van Beek FT, et al. Efficacy and safety of infliximab biosimilar Inflectra® in severe sarcoidosis. Respir Med 2018; 138S:S7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wanat KA, Rosenbach M. Case series demonstrating improvement in chronic cutaneous sarcoidosis following treatment with TNF inhibitors. Arch Dermatol 2012; 148:1097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Philips MA, Lynch J, Azmi FH. Ulcerative cutaneous sarcoidosis responding to adalimumab. J Am Acad Dermatol 2005; 53:917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heffernan MP, Smith DI. Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol 2006; 142:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Judson MA. Successful treatment of lupus pernio with adalimumab. Arch Dermatol 2011; 147:1332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pariser RJ, Paul J, Hirano S, et al. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol 2013; 68:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen GF, Wolfe CM. Recalcitrant Diffuse Cutaneous Sarcoidosis With Perianal Involvement Responding to Adalimumab. J Drugs Dermatol 2017; 16:1305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sauder MB, Beecker J, Ramsay T. Comment on 'A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis'. J Am Acad Dermatol 2014; 70:950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crommelin HA, van der Burg LM, Vorselaars AD, et al. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. Respir Med 2016; 115:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ladizinski B, Shannon EJ, Sanchez MR, Levis WR. Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders. J Drugs Dermatol 2010; 9:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliver SJ, Kikuchi T, Krueger JG, Kaplan G. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol 2002; 102:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlesimo M, Giustini S, Rossi A, et al. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 32:866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JB, Koblenzer PS. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol 1998; 39:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rousseau L, Beylot-Barry M, Doutre MS, Beylot C. Cutaneous sarcoidosis successfully treated with low doses of thalidomide. Arch Dermatol 1998; 134:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baughman RP, Judson MA, Teirstein AS, et al. Thalidomide for chronic sarcoidosis. Chest 2002; 122:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen YT, Dupuy A, Cordoliani F, et al. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol 2004; 50:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fazzi P, Manni E, Cristofani R, et al. Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids. Biomed Pharmacother 2012; 66:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Droitcourt C, Rybojad M, Porcher R, et al. A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis. Chest 2014; 146:1046.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalm VA, van Hagen PM. Efficacy of lenalidomide in refractory lupus pernio. JAMA Dermatol 2013; 149:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Damsky W, Thakral D, Emeagwali N, et al. Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis. N Engl J Med 2018; 379:2540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Damsky W, Thakral D, McGeary MK, et al. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. J Am Acad Dermatol 2020; 82:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerkemeyer KL, Meah N, Sinclair RD. Tofacitinib for cutaneous and pulmonary sarcoidosis: A case series. J Am Acad Dermatol 2021; 84:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talty R, Damsky W, King B. Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis. JAAD Case Rep 2021; 16:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman MA, Le B, Stevens J, et al. Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study. Lung 2021; 199:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alam M, Fang V, Rosenbach M. Treatment of cutaneous sarcoidosis with tofacitinib 2% ointment and extra virgin olive oil. JAAD Case Rep 2021; 9:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh K, Wang A, Heald P, et al. Treatment of angiolupoid sarcoidosis with tofacitinib ointment 2% and pulsed dye laser therapy. JAAD Case Rep 2021; 7:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosof BM. Letter: Allopurinol for sarcoid? N Engl J Med 1976; 294:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pollock JL. Sarcoidosis responding to allopurinol. Arch Dermatol 1980; 116:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brechtel B, Haas N, Henz BM, Kolde G. Allopurinol: a therapeutic alternative for disseminated cutaneous sarcoidosis. Br J Dermatol 1996; 135:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antony F, Layton AM. A case of cutaneous acral sarcoidosis with response to allopurinol. Br J Dermatol 2000; 142:1052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfau A, Stolz W, Karrer S, et al. [Allopurinol in treatment of cutaneous sarcoidosis]. Hautarzt 1998; 49:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Euch D, Mokni M, Trojjet S, et al. Sarcoidosis in a child treated successfully with allopurinol. Br J Dermatol 1999; 140:1184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voelter-Mahlknecht S, Benez A, Metzger S, Fierlbeck G. Treatment of subcutaneous sarcoidosis with allopurinol. Arch Dermatol 1999; 135:1560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samuel M, Allen GE, McMillan SC, et al. Sarcoidosis: initial results on six patients treated with allopurinol. Br J Dermatol 1984; 111:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baughman RP, Judson MA, Ingledue R, et al. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol 2012; 148:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kataria YP. Chlorambucil in sarcoidosis. Chest 1980; 78:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nowack U, Gambichler T, Hanefeld C, et al. Successful treatment of recalcitrant cutaneous sarcoidosis with fumaric acid esters. BMC Dermatol 2002; 2:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waldinger TP, Ellis CN, Quint K, Voorhees JJ. Treatment of cutaneous sarcoidosis with isotretinoin. Arch Dermatol 1983; 119:1003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaillant L, le Marchand D, Bertrand S, et al. [Annular cutaneous sarcoidosis of the forehead: treatment with isotretinoin]. Ann Dermatol Venereol 1986; 113:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Georgiou S, Monastirli A, Pasmatzi E, Tsambaos D. Cutaneous sarcoidosis: complete remission after oral isotretinoin therapy. Acta Derm Venereol 1998; 78:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bohelay G, Bouaziz JD, Nunes H, et al. Striking leflunomide efficacy against refractory cutaneous sarcoidosis. J Am Acad Dermatol 2014; 70:e111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Majithia V, Sanders S, Harisdangkul V, Wilson JG. Successful treatment of sarcoidosis with leflunomide. Rheumatology (Oxford) 2003; 42:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cagnoni ML, Lombardi A, Cerinic MC, et al. Melatonin for treatment of chronic refractory sarcoidosis. Lancet 1995; 346:1229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pignone AM, Rosso AD, Fiori G, et al. Melatonin is a safe and effective treatment for chronic pulmonary and extrapulmonary sarcoidosis. J Pineal Res 2006; 41:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kouba DJ, Mimouni D, Rencic A, Nousari HC. Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol 2003; 148:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakahigashi K, Kabashima K, Akiyama H, et al. Refractory cutaneous lichenoid sarcoidosis treated with tranilast. J Am Acad Dermatol 2010; 63:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liedtka JE. Intralesional chloroquine for the treatment of cutaneous sarcoidosis. Int J Dermatol 1996; 35:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gharavi N, Diehl J, Soriano T. Cutaneous Sarcoidosis Successfully Treated With Intralesional 5-Fluorouracil. Dermatol Surg 2015; 41:1082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drake WP, Oswald-Richter K, Richmond BW, et al. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. JAMA Dermatol 2013; 149:1040.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahnke N, Medve-Koenigs K, Megahed M, Neumann NJ. [Medium-dose UV-A1 phototherapy. Successful treatment of cutaneous sarcoidosis]. Hautarzt 2003; 54:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graefe T, Konrad H, Barta U, et al. Successful ultraviolet A1 treatment of cutaneous sarcoidosis. Br J Dermatol 2001; 145:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patterson JW, Fitzwater JE. Treatment of hypopigmented sarcoidosis with 8-methoxypsoralen and long wave ultraviolet light. Int J Dermatol 1982; 21:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gleeson CM, Morar N, Staveley I, Bunker CB. Treatment of cutaneous sarcoid with topical gel psoralen and ultraviolet A. Br J Dermatol 2011; 164:892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Momen S, Al-Niaimi F, Barlow R, Mallipeddi R. The use of lasers in cutaneous sarcoid: Is there a role? J Cosmet Laser Ther 2016; 18:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodman MM, Alpern K. Treatment of lupus pernio with the flashlamp pulsed dye laser. Lasers Surg Med 1992; 12:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cliff S, Felix RH, Singh L, Harland CC. The successful treatment of lupus pernio with the flashlamp pulsed dye laser. J Cutan Laser Ther 1999; 1:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashinoff R, Dosik JS. Treating lupus pernio with the 585 nm pulsed dye laser. Skin and Aging 1999; 7:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roos S, Raulin C, Ockenfels HM, Karsai S. Successful treatment of cutaneous sarcoidosis lesions with the flashlamp pumped pulsed dye laser: a case report. Dermatol Surg 2009; 35:1139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holzmann RD, Astner S, Forschner T, Sterry G. Scar sarcoidosis in a child: case report of successful treatment with the pulsed dye laser. Dermatol Surg 2008; 34:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ekbäck M, Molin L. Effective laser treatment in a case of lupus pernio. Acta Derm Venereol 2005; 85:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soleymani T, Abrouk M. Laser therapy for cutaneous sarcoidosis: A review. J Surg Dermatol 2016; 1:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grema H, Greve B, Raulin C. Scar sarcoidosis--treatment with the Q-switched ruby laser. Lasers Surg Med 2002; 30:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Donoghue NB, Barlow RJ. Laser remodelling of nodular nasal lupus pernio. Clin Exp Dermatol 2006; 31:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young HS, Chalmers RJ, Griffiths CE, August PJ. CO2 laser vaporization for disfiguring lupus pernio. J Cosmet Laser Ther 2002; 4:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stack BC Jr, Hall PJ, Goodman AL, Perez IR. CO2 laser excision of lupus pernio of the face. Am J Otolaryngol 1996; 17:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilsmann-Theis D, Bieber T, Novak N. Photodynamic therapy as an alternative treatment for cutaneous sarcoidosis. Dermatology 2008; 217:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karrer S, Abels C, Wimmershoff MB, et al. Successful treatment of cutaneous sarcoidosis using topical photodynamic therapy. Arch Dermatol 2002; 138:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kondo C, Watanabe D, Nakaseko H, et al. Photodynamic therapy for recurrent sarcoid flexor tenosynovitis of the finger. J Am Acad Dermatol 2006; 55:S99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patterson C. Successful treatment of cutaneous sarcoid by photodynamic therapy with minimal discomfort using a fractionated dosing regime. Photodermatol Photoimmunol Photomed 2009; 25:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Penrose C, Mercer SE, Shim-Chang H. Photodynamic therapy for the treatment of cutaneous sarcoidosis. J Am Acad Dermatol 2011; 65:e12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gürkov R, Berghaus A. Nasal reconstruction in advanced sinunasal sarcoidosis. Rhinology 2009; 47:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith R, Haeney J, Gulraiz Rauf Kh. Improving cosmesis of lupus pernio by excision and forehead flap reconstruction. Clin Exp Dermatol 2009; 34:e25.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13773 Version 27.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10430755" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10560120" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17560311" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Evidence-based therapy for cutaneous sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15764046" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Recalcitrant cutaneous sarcoidosis: an evidence-based sequential approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30895525" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Biologic Therapy in the Treatment of Cutaneous Sarcoidosis: A Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4820688" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The effects of intradermal steroids on the pituitary-adrenal axis and the skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7924231" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Cutaneous sarcoidosis: diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13044522" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Local injection of hydrocortisone and cortisone into skin lesions of sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/131575" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The place of intralesional steroid therapy in dermatology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18833787" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Clinical resolution of facial cutaneous sarcoidosis with systemic colchicine and a topical corticosteroid ointment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15725234" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Cutaneous sarcoidosis in Asians: a report of 25 patients from Singapore.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17190623" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Cutaneous sarcoidosis therapy updated.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18578557" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Evidence-based therapy for cutaneous sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1350154" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7741556" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Lupus pernio: successful treatment with a potent topical corticosteroid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17362231" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Topical tacrolimus for the treatment of cutaneous sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25073484" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Disfiguring papular sarcoidosis of the face: dramatic improvement with pimecrolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17673402" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Successful topical treatment of cutaneous sarcoidosis with macrolide immunomodulators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14634750" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : [Successful topical treatment of cutaneous sarcoidosis with tacrolimus].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12100200" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Cutaneous sarcoidosis successfully treated with topical tacrolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18086604" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Lichenoid type of cutaneous sarcoidosis: great response to topical tacrolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15732434" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Cutaneous and pulmonary sarcoidosis in association with tattoos.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24826355" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Topical pimecrolimus as a new optional treatment in cutaneous sarcoidosis of lichenoid type.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34496176" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Challenges of Sarcoidosis and Its Management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25698652" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17970883" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : New concepts in antimalarial use and mode of action in dermatology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26992838" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2064404" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Treatment of cutaneous sarcoidosis with chloroquine. Review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2212149" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5884512" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2061444" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Weekly low-dose methotrexate therapy for cutaneous sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12588537" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Difficult treatment issues in sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/911683" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Cutaneous sarcoidosis treated with methotrexate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23728635" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7717793" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Prolonged use of methotrexate for sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7670783" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9003847" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Low-dose methotrexate therapy for childhood sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5725738" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Spontaneous remission or response to methotrexate in sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24334575" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Usefulness of low-dose methotrexate monotherapy for treating sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19666758" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Sarcoidosis of the skin: a review for the pulmonologist.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8002645" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20205570" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11176663" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The use of tetracyclines for the treatment of sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23783160" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Oral minocycline in treatment of cutaneous sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17044634" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Subcutaneous nodular sarcoidosis and systemic involvement successfully treated with doxycycline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16027303" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Development of sarcoidosis in cosmetic tattoos.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18539241" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Hepatic, ocular, and cutaneous sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9041836" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Ulcerative sarcoidosis. Case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16181462" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Subcutaneous sarcoidosis--clinicopathological study of 10 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18812454" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The treatment of lupus pernio: results of 116 treatment courses in 54 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16384755" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Subcutaneous sarcoidosis: is it a specific subset of cutaneous sarcoidosis frequently associated with systemic disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4166889" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Treatment of sarcoidosis. Report of a controlled therapeutic trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10195091" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20001207" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Targeting the TNF-alpha pathway in sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28564695" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Efficacy and Tolerance of Anti-Tumor Necrosis FactorαAgents in Cutaneous Sarcoidosis: A French Study of 46 Cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20185892" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19423648" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17985415" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17417999" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22398084" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21899592" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20808167" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Tumor necrosis factor-alpha antagonist-induced sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18578973" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26419478" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : TNF-α: a treatment target or cause of sarcoidosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20831604" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19468200" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25034562" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16840744" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25078637" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Practical eminence and experience-based recommendations for use of TNF-αinhibitors in sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30446173" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Anti-tumor necrosis factor agents in sarcoidosis: A systematic review of efficacy and safety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18256069" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26847095" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26847093" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Infliximab or biosimilars in sarcoidosis; to switch or not to switch?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Promising results of the infliximab Biosimilar Inflectra in severe sarcoidosis patients. B104 Sarcoidosis: Clinical studies on diagnosis, prognosis and therapy
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29496351" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Efficacy and safety of infliximab biosimilar Inflectra®in severe sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22986883" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Case series demonstrating improvement in chronic cutaneous sarcoidosis following treatment with TNF inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16243166" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Ulcerative cutaneous sarcoidosis responding to adalimumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16415380" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Adalimumab for treatment of cutaneous sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22106129" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Successful treatment of lupus pernio with adalimumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23276549" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29240869" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Recalcitrant Diffuse Cutaneous Sarcoidosis With Perianal Involvement Responding to Adalimumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24742841" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Comment on 'A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis'.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27215507" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20677538" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11890709" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7722046" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Treatment of cutaneous and pulmonary sarcoidosis with thalidomide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9810910" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9722748" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Cutaneous sarcoidosis successfully treated with low doses of thalidomide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12114363" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Thalidomide for chronic sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14726878" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Treatment of cutaneous sarcoidosis with thalidomide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22494798" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24945194" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23715134" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Efficacy of lenalidomide in refractory lupus pernio.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30586518" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31185230" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33075414" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Tofacitinib for cutaneous and pulmonary sarcoidosis: A case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34522749" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33825964" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33598514" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Treatment of cutaneous sarcoidosis with tofacitinib 2% ointment and extra virgin olive oil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33426249" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Treatment of angiolupoid sarcoidosis with tofacitinib ointment 2% and pulsed dye laser therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1246320" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Letter: Allopurinol for sarcoid?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7369740" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Sarcoidosis responding to allopurinol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8881681" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Allopurinol: a therapeutic alternative for disseminated cutaneous sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10809876" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : A case of cutaneous acral sarcoidosis with response to allopurinol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9565790" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : [Allopurinol in treatment of cutaneous sarcoidosis].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10354102" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Sarcoidosis in a child treated successfully with allopurinol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10606082" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Treatment of subcutaneous sarcoidosis with allopurinol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Sarcoidosis: initial results on six patients treated with allopurinol
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22004880" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Efficacy and safety of apremilast in chronic cutaneous sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7471842" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Chlorambucil in sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12498617" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Successful treatment of recalcitrant cutaneous sarcoidosis with fumaric acid esters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6580843" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Treatment of cutaneous sarcoidosis with isotretinoin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3468869" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : [Annular cutaneous sarcoidosis of the forehead: treatment with isotretinoin].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9833048" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Cutaneous sarcoidosis: complete remission after oral isotretinoin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15127974" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Leflunomide for chronic sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24742855" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Striking leflunomide efficacy against refractory cutaneous sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12709556" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Successful treatment of sarcoidosis with leflunomide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7475684" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Melatonin for treatment of chronic refractory sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16879313" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Melatonin is a safe and effective treatment for chronic pulmonary and extrapulmonary sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12534610" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20542186" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Refractory cutaneous lichenoid sarcoidosis treated with tranilast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8876312" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Intralesional chloroquine for the treatment of cutaneous sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26317811" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Cutaneous Sarcoidosis Successfully Treated With Intralesional 5-Fluorouracil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23863960" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12669212" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : [Medium-dose UV-A1 phototherapy. Successful treatment of cutaneous sarcoidosis].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11531812" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Successful ultraviolet A1 treatment of cutaneous sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7174183" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Treatment of hypopigmented sarcoidosis with 8-methoxypsoralen and long wave ultraviolet light.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21143466" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Treatment of cutaneous sarcoid with topical gel psoralen and ultraviolet A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26962971" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : The use of lasers in cutaneous sarcoid: Is there a role?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1406009" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Treatment of lupus pernio with the flashlamp pulsed dye laser.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11360426" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : The successful treatment of lupus pernio with the flashlamp pulsed dye laser.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Treating lupus pernio with the 585 nm pulsed dye laser
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19438681" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Successful treatment of cutaneous sarcoidosis lesions with the flashlamp pumped pulsed dye laser: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18190544" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Scar sarcoidosis in a child: case report of successful treatment with the pulsed dye laser.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16396801" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Effective laser treatment in a case of lupus pernio.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Laser therapy for cutaneous sarcoidosis: A review
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12116334" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Scar sarcoidosis--treatment with the Q-switched ruby laser.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16309473" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Laser remodelling of nodular nasal lupus pernio.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12623554" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : CO2 laser vaporization for disfiguring lupus pernio.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8827292" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : CO2 laser excision of lupus pernio of the face.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18799881" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Photodynamic therapy as an alternative treatment for cutaneous sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12020217" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Successful treatment of cutaneous sarcoidosis using topical photodynamic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17052549" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Photodynamic therapy for recurrent sarcoid flexor tenosynovitis of the finger.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19747248" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Successful treatment of cutaneous sarcoid by photodynamic therapy with minimal discomfort using a fractionated dosing regime.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21679796" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Photodynamic therapy for the treatment of cutaneous sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19839261" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Nasal reconstruction in advanced sinunasal sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19508469" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Improving cosmesis of lupus pernio by excision and forehead flap reconstruction.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
